Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 3/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30395677 | 0.88 | PPARD (0.56) | PPARDPPARASRD5A2PPARGBCL2 | |
| SCHEMBL4478676 | 0.88 | PPARD (0.56) | PPARDPPARASRD5A2PPARGBCL2 | |
| SCHEMBL6384598 | 0.88 | SRD5A2 (0.55) | PPARDPPARASRD5A2HDAC1HDAC6 | |
| SCHEMBL3862821 | 0.88 | PPARD (0.72) | PPARDPPARASRD5A2HDAC1HDAC6 | |
| SCHEMBL9200019 | 0.83 | MTNR1A (0.60) | HDAC1HDAC6 | |
| SCHEMBL4048508 | 0.81 | MAPK14 (0.65) | — | |
| SCHEMBL5762625 | 0.81 | GAA (0.54) | PPARDPPARASRD5A2NPC1RAB9A | |
| SCHEMBL6385516 | 0.81 | ITGB3 (0.60) | PPARDPPARASRD5A2BCL2MCL1 | |
| SCHEMBL1180094 | 0.80 | BCL2 (0.54) | PPARDPPARASRD5A2HDAC1HDAC6 | |
| SCHEMBL9200310 | 0.80 | SRD5A2 (0.53) | PPARDPPARASRD5A2PPARGBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244763-B2 | Compounds that modulate PPAR activity and methods of preparation | WARNER LAMBERT COMPANY LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | SHIONOGI & CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1690538-A1 | ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2006-08-16 | — | — | EP | disclosed |
| US-6875780-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | BRATTON LARRY D (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885SRD5A2 1196/4885 |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARA 243/4885SRD5A2 595/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARA 243/4885SRD5A2 595/4885 |
| US-20070054902-A1 | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists | NR1H3, NR1H2, RXRA | PPARD 4/4885PPARA 6/4885SRD5A2 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.